Vaccines Today—March 13, 2026

This week’s Vaccines Research update highlights clinical progress, durable efficacy data, manufacturing partnerships, regional supply expansion, and continued momentum in pandemic preparedness and immunoprevention.

In Today’s Newsletter

Dive deeper

🧬 Anixa Biosciences expands breast cancer vaccine IP in South Korea [1] [South Korea • 09 Mar 2026]

https://www.stocktitan.net/news/ANIX/anixa-biosciences-receives-notice-of-allowance-from-korean-ministry-ljcjfz2bu9se.html
Context: Anixa Biosciences said the Korean Ministry of Intellectual Property issued a notice of allowance for a patent titled Vaccine Adjuvants and Formulations.
Key point: The allowance extends protection for Anixa’s Cleveland Clinic-licensed breast cancer vaccine platform in South Korea.
Implication: Signals pipeline investment and modality expansion.

🦠 EuBiologics teams with KDCA NIH on a Nipah vaccine candidate [2] [South Korea • 10 Mar 2026]

https://www.kedglobal.com/bio-pharma/newsView/ked202603100001
Context: EuBiologics is developing a nanoparticle-based Nipah virus vaccine candidate with the National Institute of Health of the Korea Disease Control and Prevention Agency.
Key point: The government-backed program runs from Apr 2025 to Dec 2026 and is aimed at rapid-response platforms for pandemic-priority pathogens.
Implication: Signals pipeline investment and modality expansion.

💉 ETVAX shows pediatric protection against ETEC in Gambia [3] [Gambia • 10 Mar 2026]

https://www.yahoo.com/news/articles/first-kind-vaccine-protects-children-150000171.html
Context: The report describes a large pediatric study in Gambia evaluating ETVAX, an oral vaccine for enterotoxigenic Escherichia coli (ETEC).
Key point: ETVAX was reported as protective in children and well tolerated, supporting further late-stage development.
Implication: May influence prescriber choice and payer reviews pending full data.

🌎 CSL Seqirus, PAHO and Sinergium Biotech localize flu vaccine supply in LATAM [4] [LATAM • 10 Mar 2026]

https://www.csl.com/news/2026/20260310-seqirus-signs-long-term-agreement-with-paho
Context: CSL Seqirus signed a multi-year agreement with the PAHO Regional Revolving Fund and will work with Sinergium Biotech in Argentina on local filling and distribution.
Key point: The partners said the deal will expand regional influenza vaccine manufacturing capacity and support sustainable supply.
Implication: May expand screening, initiation, and follow-up at scale.

🧫 GC Biopharma publishes 30-year review of MAV/06 varicella data [5] [South Korea • 11 Mar 2026]

https://www.prnewswire.com/news-releases/gc-biopharma-publishes-a-comprehensive-review-paper-summarizing-30-years-of-accumulated-data-on-its-proprietary-varicella-vaccine-strain-mav06-302710519.html
Context: GC Biopharma said a review in Human Vaccines & Therapeutics analyzed more than 40 studies spanning clinical, post-marketing, real-world, and genomic data.
Key point: The paper summarizes long-term safety and immunogenicity findings for the company’s MAV/06 varicella vaccine strain.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🦟 Butantan reports five-year durability for Butantan-DV dengue vaccine [6] [Brazil • 11 Mar 2026]

https://agencia.fapesp.br/dengue-vaccine-remains-805-effective-against-severe-cases-after-five-years/57407
Context: A Phase 3 study published in Nature Medicine followed participants across Brazil for five years after a single-dose tetravalent dengue vaccine.
Key point: Butantan Institute reported durable protection against severe dengue cases with warning signs, alongside protection against symptomatic dengue.
Implication: May influence prescriber choice and payer reviews pending full data.

🤝 Bavarian Nordic and Serum Institute expand chikungunya vaccine manufacturing pact [7] [Denmark–India • 11 Mar 2026]

https://www.biospace.com/bavarian-nordic-and-serum-institute-of-india-expand-strategic-partnership-with-chikungunya-vaccine-manufacturing-agreement
Context: Bavarian Nordic expanded its partnership with Serum Institute of India to include full tech transfer for CHIKV VLP manufacturing.
Key point: The agreement is intended to scale future supply of the chikungunya vaccine to endemic low- and middle-income countries.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Vaccine news this week spans prevention, access, and manufacturing, from cancer immunoprevention to dengue, influenza, varicella, ETEC, Nipah, and chikungunya.
Several items focus on regional supply resilience, especially LATAM influenza manufacturing [4] and LMIC chikungunya access planning [7].
South Korea featured prominently in both vaccine R&D and IP, via EuBiologics’ Nipah program [2], GC Biopharma’s varicella publication [5], and Anixa’s patent allowance [1].
Late-stage and long-duration datasets remain central for differentiation, including ETVAX pediatric efficacy reporting [3] and five-year dengue durability from Butantan-DV [6].
Partnership structures continue to shape vaccine expansion, with public-sector, academic, and manufacturing alliances across multiple programs [1][2][4][7].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Vaccines archive on our research hub page.

FAQ

What happened with Anixa Biosciences’ breast cancer vaccine program?

Anixa Biosciences said South Korea’s intellectual property office issued a notice of allowance for a patent covering aspects of its breast cancer vaccine technology. The company framed this as an expansion of global IP around its Cleveland Clinic-licensed platform [1].

What is notable about the EuBiologics Nipah project?

EuBiologics is working with the KDCA National Institute of Health on a nanoparticle-based Nipah vaccine candidate using a consensus-based antigen and adjuvant. The program is government-backed and positioned for pandemic preparedness, with nonclinical work underway [2].

Why is ETVAX getting attention now?

The cited report says ETVAX is the first vaccine to show significant protection against pathogenic E. coli infections in children in a large pediatric setting. The article also says an EMA-approved Phase 3 trial is planned in infants from low- and middle-income countries [3].

What does the CSL Seqirus and PAHO agreement change?

CSL Seqirus will supply influenza vaccines under a long-term PAHO arrangement and work with Sinergium Biotech on local filling and distribution in Argentina. The stated goal is more reliable, scalable regional supply and stronger pandemic readiness in the Americas [4].

What did GC Biopharma publish on MAV/06?

GC Biopharma announced a review paper compiling three decades of safety and immunogenicity data for its MAV/06 varicella vaccine strain. The company said the paper covered clinical studies, post-marketing data, real-world evidence, and genomic analyses [5].

What is the latest from Butantan-DV and CHIKV VLP?

Butantan Institute reported five-year Phase 3 data showing continued protection for its tetravalent dengue vaccine and noted prior ANVISA approval in Brazil [6]. Separately, Bavarian Nordic expanded its Serum Institute partnership to transfer chikungunya vaccine manufacturing for future LMIC supply [7].

Entities / Keywords

Anixa Biosciences, Cleveland Clinic, breast cancer vaccine, α-lactalbumin, cancer immunotherapy
EuBiologics, KDCA, Korea Disease Control and Prevention Agency, National Institute of Health, Nipah virus, nanoparticle vaccine
ETVAX, Scandinavian Biopharma, ETEC, enterotoxigenic Escherichia coli, pediatric diarrhea, Gambia
CSL Seqirus, PAHO, Pan American Health Organization, Sinergium Biotech, influenza vaccine, cell-based flu vaccine, MF59
GC Biopharma, MAV/06, BARYCELA, varicella vaccine, chickenpox vaccine
Butantan Institute, Butantan-DV, dengue vaccine, ANVISA, Nature Medicine
Bavarian Nordic, Serum Institute of India, CHIKV VLP, Vimkunya, chikungunya vaccine, tech transfer